JP2005526711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526711A5 JP2005526711A5 JP2003560027A JP2003560027A JP2005526711A5 JP 2005526711 A5 JP2005526711 A5 JP 2005526711A5 JP 2003560027 A JP2003560027 A JP 2003560027A JP 2003560027 A JP2003560027 A JP 2003560027A JP 2005526711 A5 JP2005526711 A5 JP 2005526711A5
- Authority
- JP
- Japan
- Prior art keywords
- helicobacter pylori
- nac
- binding substance
- group
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000590002 Helicobacter pylori Species 0.000 claims description 65
- 229940037467 helicobacter pylori Drugs 0.000 claims description 65
- 230000027455 binding Effects 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 50
- 150000002482 oligosaccharides Polymers 0.000 claims description 40
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 29
- 101150026303 HEX1 gene Proteins 0.000 claims description 21
- 150000002772 monosaccharides Chemical group 0.000 claims description 18
- 125000006850 spacer group Chemical group 0.000 claims description 14
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 13
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 12
- 229930182830 galactose Natural products 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003198 secondary alcohol group Chemical group 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 12
- 235000015872 dietary supplement Nutrition 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000010065 bacterial adhesion Effects 0.000 claims 2
- VOIFKEWOFUNPBN-QIUUJYRFSA-N beta-D-glucuronamide Chemical group NC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O VOIFKEWOFUNPBN-QIUUJYRFSA-N 0.000 claims 2
- 229950004542 glucuronamide Drugs 0.000 claims 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000034972 Sudden Infant Death Diseases 0.000 claims 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 235000008452 baby food Nutrition 0.000 claims 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical group CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 150000004676 glycans Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000018556 stomach disease Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 150000002402 hexoses Chemical group 0.000 description 5
- 150000002339 glycosphingolipids Chemical class 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/FI2002/000043 WO2002056893A1 (en) | 2001-01-19 | 2002-01-18 | Novel receptors for $i(helicobacter pylori) and use thereof |
| PCT/FI2003/000039 WO2003059924A1 (en) | 2002-01-18 | 2003-01-20 | Novel binding epitopes for helicobacter pylori and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526711A JP2005526711A (ja) | 2005-09-08 |
| JP2005526711A5 true JP2005526711A5 (enExample) | 2006-03-09 |
Family
ID=8555940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003560027A Pending JP2005526711A (ja) | 2002-01-18 | 2003-01-20 | ヘリコバクターピロリに対する新規結合エピトープおよびその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050220819A1 (enExample) |
| EP (1) | EP1476454A1 (enExample) |
| JP (1) | JP2005526711A (enExample) |
| AU (1) | AU2003201619A1 (enExample) |
| IN (1) | IN2003KO00855A (enExample) |
| WO (1) | WO2003059924A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20021989A0 (fi) * | 2002-11-06 | 2002-11-06 | Halina Miller-Podraza | Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö |
| WO2004065400A1 (en) * | 2003-01-20 | 2004-08-05 | Glykos Finland Oy | Novel binding epitopes for helicobacter pylori and use thereof |
| US7651847B2 (en) * | 2004-06-22 | 2010-01-26 | The Regents Of The University Of California | Methods of oligosaccharide profiling for the detection of cancer |
| FI20055417A0 (fi) * | 2005-07-20 | 2005-07-20 | Glykos Finland Oy | Syöpäpesifiset glykaanit ja niiden käyttö |
| WO2007023867A1 (ja) * | 2005-08-24 | 2007-03-01 | Seikagaku Corporation | 新規コンドロイチン画分製造方法 |
| JP5035787B2 (ja) * | 2005-10-04 | 2012-09-26 | 焼津水産化学工業株式会社 | α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤 |
| GB0524782D0 (en) * | 2005-12-05 | 2006-01-11 | Chiron Srl | Analysis of samples |
| EP1988786B2 (en) * | 2006-02-10 | 2019-10-09 | Société des Produits Nestlé S.A. | Oligosaccharide mixture |
| JP5014018B2 (ja) * | 2006-10-18 | 2012-08-29 | 旭化成ケミカルズ株式会社 | ピロリ菌の抑制剤または静菌剤 |
| EP3184536A1 (en) * | 2015-12-22 | 2017-06-28 | Westfälische Wilhelms-Universität Münster | Oligosaccharide composition for binding to lectins |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3405120A (en) * | 1966-01-27 | 1968-10-08 | Green Cross Corp | Low molecular chondroitin sulfate and method for manufacturing the same |
| FR2535324A1 (fr) * | 1982-10-27 | 1984-05-04 | Choay Sa | Station perfectionnee pour l'epuration d'eaux usees |
| GB8519416D0 (en) * | 1985-08-01 | 1985-09-04 | Unilever Plc | Oligosaccharides |
| CN1036386A (zh) * | 1988-04-07 | 1989-10-18 | 张锦 | D-氨基半乳糖盐酸盐的制备方法 |
| US5874261A (en) * | 1988-09-02 | 1999-02-23 | The Trustees Of The University Of Pennsylvania | Method for the purification of glycosyltransferases |
| US6492349B1 (en) * | 1993-03-31 | 2002-12-10 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
| JPH1045602A (ja) * | 1996-07-31 | 1998-02-17 | Motoyasu Murakami | ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤 |
| SE9904581D0 (sv) * | 1999-12-15 | 1999-12-15 | A & Science Invest Ab | A novel helicobacter pylori-binding substance and use thereof |
| FI20010118A7 (fi) * | 2001-01-19 | 2002-07-20 | Carbion Oy | Uudet helicobacter pylori reseptorit ja niiden käyttö |
| FI20011403L (fi) * | 2001-06-29 | 2002-12-30 | Carbion Oy | Menetelmä ja koostumukset vatsan sairauksien hoitoon |
-
2003
- 2003-01-20 AU AU2003201619A patent/AU2003201619A1/en not_active Abandoned
- 2003-01-20 EP EP03700317A patent/EP1476454A1/en not_active Withdrawn
- 2003-01-20 JP JP2003560027A patent/JP2005526711A/ja active Pending
- 2003-01-20 WO PCT/FI2003/000039 patent/WO2003059924A1/en not_active Ceased
- 2003-01-20 US US10/501,786 patent/US20050220819A1/en not_active Abandoned
- 2003-07-02 IN IN855KO2003 patent/IN2003KO00855A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rudiger et al. | Medicinal chemistry based on the sugar code: fundamentals of lectinology and experimental strategies with lectins as targets | |
| EP2144920B1 (en) | Sulphated amino sugars with anti-inflammatory properties | |
| JP5219329B2 (ja) | 下痢の予防又は治療用の医薬組成物 | |
| AU2009274630B2 (en) | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | |
| Monsigny et al. | Sugar-lectin interactions: sugar clusters, lectin multivalency and avidity | |
| JP2005526711A5 (enExample) | ||
| Behera et al. | Chemical synthesis of rare, deoxy-amino sugars containing bacterial glycoconjugates as potential vaccine candidates | |
| Lingwood | Oligosaccharide receptors for bacteria: a view to a kill | |
| CA2443774A1 (en) | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation | |
| RU2306140C2 (ru) | НОВЫЕ РЕЦЕПТОРЫ ДЛЯ Helicobacter pylori И ИХ ПРИМЕНЕНИЕ | |
| JP2004519459A5 (enExample) | ||
| JP2003517015A5 (enExample) | ||
| US20030130205A1 (en) | Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use | |
| JPS59176300A (ja) | 治療または診断上有用な化合物および組成物 | |
| CA2272701C (en) | Glycolipid mimics and methods of use thereof | |
| AU2002229792A1 (en) | Novel receptors for Helicobacter pylori and use thereof | |
| JPH11508564A (ja) | 合成ｎ−結合グリココンジュゲートを製造するための方法 | |
| US20050220819A1 (en) | Novel binding epitopes for helicobacter pylori and use thereof | |
| TW474814B (en) | Pharmaceutical compositions useful in treating traveller's diarrhea and related conditions initiated by enterotoxigenic E. coli | |
| Wu et al. | Stereoselective Synthesis and Immunological Evaluation of Common O‐antigen of P. mirabilis OE and P. vulgaris TG103 | |
| DE69713514T2 (de) | Festphasenträgeroberfläche die toxin-bindende oligosaccharide enthalten | |
| JPH04507244A (ja) | リピドａ類似体／免疫原性担体コンジュゲートおよびそのワクチンとしての使用 | |
| WO2004065400A1 (en) | Novel binding epitopes for helicobacter pylori and use thereof | |
| BRPI0013686B1 (pt) | procedimento para sintetizar uma mistura de oligossacarídeos | |
| Nikolaev et al. | Synthetic glycoconjugates based on Leishmania lipophosphoglycan structures as |